睿知中国医院研究地图
候选清单

杭州浙江大学医学院

浙江大学医学院附属第二医院

Second Affiliated Hospital, Zhejiang University

在本站收录的 53 种疾病中,这家医院列在其中 33 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

浙江大学医学院附属第二医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma1 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文牵头 3 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma68 篇牵头论文牵头 9 项开放试验
  4. 胃癌Stomach cancer59 篇牵头论文牵头 6 项开放试验
  5. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  6. 脊索瘤Chordoma0 篇牵头论文
  7. 骨肉瘤Osteosarcoma16 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour5 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma3 篇牵头论文
  10. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma5 篇牵头论文牵头 2 项开放试验
  12. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  13. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  14. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder7 篇牵头论文
  15. 重症肌无力Myasthenia gravis4 篇牵头论文
  16. 烟雾病Moyamoya disease12 篇牵头论文
  17. 肝豆状核变性Wilson disease8 篇牵头论文牵头 2 项开放试验
  18. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis4 篇牵头论文
  19. 大动脉炎Takayasu arteritis0 篇牵头论文
  20. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  21. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis6 篇牵头论文
  22. 法布雷病Fabry disease0 篇牵头论文
  23. 庞贝病Pompe disease0 篇牵头论文
  24. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  25. 白塞病Behçet disease0 篇牵头论文
  26. Alport 综合征Alport syndrome1 篇牵头论文
  27. IgA 肾病IgA nephropathy2 篇牵头论文
  28. 成骨不全症Osteogenesis imperfecta0 篇牵头论文
  29. 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文
  30. 先天性巨结肠Hirschsprung disease1 篇牵头论文
  31. 遗传性血管性水肿Hereditary angioedema1 篇牵头论文
  32. 家族性腺瘤性息肉病Familial adenomatous polyposis4 篇牵头论文
  33. Leber 遗传性视神经病变Leber hereditary optic neuropathy0 篇牵头论文

未列出的收录疾病:肝母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、IgG4相关性疾病、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、戈谢病、尼曼-匹克病 C 型、原发性胆汁性胆管炎、原发性硬化性胆管炎、遗传性大疱性表皮松解症、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

杭州有 8 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

杭州有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-06
    登记号
    NCT07244978

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  2. 正在招募
    Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07505186

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  3. 正在招募
    Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-08
    登记号
    NCT06576973

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗免疫治疗影像与人工智能
牵头的论文4
  1. Discovery of LD-110 as an Effective LSD1 PROTAC Degrader for the Treatment of Esophagus Squamous Cancer.2025Journal of medicinal chemistry免费全文
  2. Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial.2025Nature communications免费全文
  3. Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration.2024Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  4. Long Non-Coding RNA OIP5-AS1 Inhibits the Proliferation and Migration of Esophageal Squamous Carcinoma Cells by Targeting FOXD1/miR-30a-5p Axis and the Effect of Micro- and Nano-Particles on Targeting Transfection System.2021Journal of biomedical nanotechnology
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma正在招募NCT07505186牵头方II期2026-08 启动
  2. Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma正在招募NCT07244978牵头方II期2026-06 启动
  3. Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma正在招募NCT06576973牵头方II期2024-08 启动
  4. Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy状态不明NCT05990231牵头方II期2023-09 启动
  5. Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma进行中,不再招募NCT05659251牵头方II期2022-12 启动
  6. Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04666090牵头方II期2020-11 启动
  7. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  8. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  9. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
PubMed 以外找到的论文(未计入)8
  1. 1319 First-in-human study of a personalized neoantigen peptide vaccine (iNeo-Vac-P01) for postoperative esophageal cancer in a Chinese cohort2025Journal for ImmunoTherapy of Cancer会议摘要
  2. Abstract 2876: Spatial immune cell atlas predicts the sensitivity to neoadjuvant PD-1 blockade treatment combined with radiotherapy in resectable esophageal squamous cell carcinoma2024Cancer Research会议摘要
  3. Clinical long-term oncologic outcomes of endoscopic noncurative resection for superficial esophageal squamous cell carcinoma: A single-center retrospective study2024Research Square预印本
  4. Clinical pathological characteristics and expression of 328 proteins and their impact on survival in over 20,000 cases of esophageal squamous cell carcinoma and colorectal adenocarcinoma2024Chinese Science Bulletin (Chinese Version)论文
  5. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncology会议摘要
  6. Abstract 6124: Interleukin-1β and exosomal M6PR secreted by serglycin-overexpressing esophageal cancer cells instigate fibroblasts and endothelial cells to promote esophageal cancer progression2022Cancer Research会议摘要
  7. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figshare数据集
  8. Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 68 篇,占 0.5%。

牵头论文
68
2021–2025 年
牵头试验
27
任何状态,ClinicalTrials.gov
牵头的开放试验
9
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 161620222023: 121220232024: 9920242025: 19192025

杭州有 7 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 13

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
    分期
    II期
    开始
    2026-03
    登记号
    NCT07422753

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  2. 正在招募
    Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07417800

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  3. 正在招募
    Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
    分期
    不分期
    开始
    2024-09
    登记号
    NCT06542796

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  4. 正在招募
    Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
    分期
    未注明
    开始
    2024-02
    登记号
    NCT06544083

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  5. 正在招募
    Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
    分期
    不分期
    开始
    2023-05
    登记号
    NCT05596630

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  6. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

  7. 正在招募
    RFA Plus Carrizumab vs Carrizumab Alone for HCC
    分期
    II期
    开始
    2020-08
    登记号
    NCT04150744

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  8. 即将招募
    Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
    分期
    II期
    开始
    2026-01
    登记号
    NCT07328802

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  9. 即将招募
    Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
    分期
    不分期
    开始
    2023-03
    登记号
    NCT05602974

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  10. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  11. 正在招募
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    分期
    I期
    开始
    2023-10
    登记号
    NCT06560827

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙

  12. 即将招募
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07596134

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心南昌、台州、杭州

  13. 即将招募
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07100236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、广州、杭州、温州、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像、人工智能与早期发现复发与预后免疫与靶向药物
论文中的科室普外/肝胆胰外科影像/核医学科肿瘤内科放疗科

这些论文过半是实验室或动物研究。

牵头的论文68
  1. Quantitative analysis of enhanced CT in predicting microvascular invasion and pathological grading of hepatocellular carcinoma.2026European radiology
  2. A pH-Sensitive Nanosized Covalent-Organic Polymer for Enhanced Tumor Photodynamic Immunotherapy by Hypoxia Relief and STAT3 Inhibition.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Lactate drives senescence-resistant lineages in hepatocellular carcinoma via histone H2B lactylation of NDRG1.2025Cancer letters
  4. Network meta-analysis of the efficacy and safety of ablation for hepatocellular carcinoma under different imaging guidance.2025Clinical radiology
  5. Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma.2025Frontiers in immunology免费全文
  6. SPP1 promotes malignant characteristics and drug resistance in hepatocellular carcinoma by activating fatty acid metabolic pathway.2025Functional & integrative genomics
  7. METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.2025Future oncology (London, England)免费全文
  8. Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases.2025International journal of nanomedicine免费全文
  9. Redox-driven hybrid nanoenzyme dynamically activating ferroptosis and disulfidptosis for hepatocellular carcinoma theranostics.2025Journal of colloid and interface science
  10. A Conserved FABP5high Macrophage Subset Promotes Fibrosis and Carcinogenesis in Advanced Liver Disease.2025Liver international : official journal of the International Association for the Study of the Liver免费全文
  11. Hepatic micropeptide modulates mitochondrial RNA processing machinery in hepatocellular carcinoma.2025Molecular cell
  12. A long-term self-driven metronomic photodynamic system for cancer therapy.2025Nature communications免费全文
  13. Mendelian randomization and nomogram-based prediction of hepatocellular carcinoma risk in patients with hepatitis B cirrhosis.2025PeerJ免费全文
  14. Efficacy and safety of stereotactic body radiotherapy for hepatocellular carcinoma with tumor thrombus in right atrium: a two-center retrospective review.2025Radiation oncology (London, England)免费全文
  15. Multi-omic analysis reveals elevated BRI3BP expression associated with hepatocellular carcinoma progression and poor prognosis.2025Scientific reports免费全文
  16. Bicarbonate-integrated transarterial chemoembolization (TACE) in real-world hepatocellular carcinoma.2025Signal transduction and targeted therapy免费全文
  17. Pharmacological mechanisms of carvacrol against hepatocellular carcinoma by network pharmacology and molecular docking.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  18. RHEB neddylation by the UBE2F-SAG axis enhances mTORC1 activity and aggravates liver tumorigenesis.2025The EMBO journal免费全文
  19. Autophagy inhibitor-sensitized artificially activated neutrophils against hepatocellular carcinoma.2025Theranostics免费全文
  20. Modified CEUS LI-RADS With Perfluorobutane in Patients at High-Risk for Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.2025Ultrasound in medicine & biology
  21. Radiomics-based Machine Learning to Predict the Recurrence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2024Academic radiology
  22. Aggregation-induced emission: Application in diagnosis and therapy of hepatocellular carcinoma.2024Biosensors & bioelectronics
  23. Poly(lactic acid hydroxyacetic acid)-poly(ethylene glycol)-modified ginsenoside Rg3 nanomedicine enhances anti-tumor effect in hepatocellular carcinoma.2024Drug development and industrial pharmacy
  24. Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer.2024Frontiers in immunology免费全文
  25. Effects of sinomenine on a rat orthotopic liver carcinoma model.2024Histology and histopathology
  26. Transcription Factor E2F1 Enhances Hepatocellular Carcinoma Cell Proliferation and Stemness by Activating GINS1.2024Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  27. Macrophages as Targets in Hepatocellular Carcinoma Therapy.2024Molecular cancer therapeutics
  28. Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.2024Molecular medicine (Cambridge, Mass.)免费全文
  29. A Poly(amino acid)-Based Nanomedicine Strategy: Telomere-Telomerase Axis Targeting and Magnetic Resonance Imaging in Hepatocellular Carcinoma Treatment.2024Nano letters
  30. EphrinB2 drives osteogenic fate of adult cardiac fibroblasts in a calcium influx dependent manner.2023American journal of physiology. Cell physiology
  31. Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics.2023Cancer letters
  32. Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.2023Clinical and experimental medicine
  33. Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study.2023Clinics and research in hepatology and gastroenterology
  34. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab.2023Frontiers in immunology免费全文
  35. 5'-tiRNA-Gln inhibits hepatocellular carcinoma progression by repressing translation through the interaction with eukaryotic initiation factor 4A-I.2023Frontiers of medicine
  36. TRPM2 regulates cell cycle through the Ca2+-CaM-CaMKII signaling pathway to promote HCC.2023Hepatology communications免费全文
  37. m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  38. A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma.2023Journal of cellular and molecular medicine免费全文
  39. Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model.2023Molecular pharmaceutics
  40. Expression and prognostic impact of NTF3 and TrkC in hepatocellular carcinoma.2023Scandinavian journal of gastroenterology
  41. Response to Letter to the Editor Regarding the Article "Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement" by Zhou and Collaborato2023Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  42. Identification of Immune-Related Markers in Hepatocellular Carcinoma Based on Gene Co-expression Network.2022Biochemical genetics
  43. Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.2022Bioorganic chemistry
  44. Transfer RNA-derived fragment 5'tRF-Gly promotes the development of hepatocellular carcinoma by direct targeting of carcinoembryonic antigen-related cell adhesion molecule 1.2022Cancer science免费全文
  45. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma.2022Cell death & disease免费全文
  46. Genetic dominance of transforming growth factor-β1 polymorphisms in chronic liver disease.2022Frontiers in immunology免费全文
  47. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.2022Frontiers in immunology免费全文
  48. Nanosecond pulsed electric field interrupts the glycogen metabolism in hepatocellular carcinoma by modifying the osteopontin pathway.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  49. SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis.2022International journal of biological sciences免费全文
  50. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.2022Journal for immunotherapy of cancerRCT免费全文
  51. Treatment of microvascular invasion in hepatocellular carcinoma with drug-loaded nanocomposite platform under synergistic effect of magnetic field/near-infrared light.2022Journal of biomedical materials research. Part B, Applied biomaterials
  52. The role of AURKA/miR-199b-3p in hepatocellular carcinoma cells.2022Journal of clinical laboratory analysis免费全文
  53. Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.2022Journal of gastroenterology and hepatology
  54. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.2022Journal of nanobiotechnology免费全文
  55. Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function.2022Oncogene
  56. Circulating MicroRNA Panel as a Diagnostic Marker for Hepatocellular Carcinoma.2022The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  57. Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement.2022Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  58. Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma.2021BioMed research international免费全文
  59. Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway.2021Biochimica et biophysica acta. Molecular basis of disease
  60. REPLY.2021Hepatology (Baltimore, Md.)
  61. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.2021International journal of biological sciences免费全文
  62. Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis.2021Journal of nanobiotechnology免费全文
  63. RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  64. CEUS examination of the outcome of radiofrequency ablation of canine prostate lesions.2021Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  65. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.2021Molecular medicine reports免费全文
  66. Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma.2021Scientific reports免费全文
  67. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment.2021The Journal of international medical research免费全文
  68. CT radiomics nomogram for the preoperative prediction of severe post-hepatectomy liver failure in patients with huge (≥ 10 cm) hepatocellular carcinoma.2021World journal of surgical oncology免费全文
中文论文(未计入)3
  1. [New perspective of diagnosis and treatment of hepatocellular carcinoma complicated with portal vein tumor thrombosis].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Progress in surgical treatment of hepatocellular carcinoma with tumor thrombus in the inferior vena cava].2023Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [The clinical value of terminal branches portal vein embolization for hepatocellular carcinoma with insufficient future liver remnant].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
它在 ClinicalTrials.gov 上的全部试验(任何状态)34
  1. Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma即将招募NCT07328802牵头方II期2026-01 启动
  2. A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC正在招募NCT07422753牵头方II期2026-03 启动
  3. Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning正在招募NCT07417800牵头方2025-11 启动
  4. Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma正在招募NCT06542796牵头方不分期2024-09 启动
  5. Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood正在招募NCT06544083牵头方2024-02 启动
  6. Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC正在招募NCT05596630牵头方不分期2023-05 启动
  7. Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study即将招募NCT05602974牵头方不分期2023-03 启动
  8. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413牵头方2022-09 启动
  9. RFA Plus Carrizumab vs Carrizumab Alone for HCC正在招募NCT04150744牵头方II期2020-08 启动
  10. Single-Arm Clinical Study of Icaritin Soft Capsules as Adjuvant Therapy for Hepatocellular Carcinoma Patients at High Risk of Postoperative Recurrence进行中,不再招募NCT07328828牵头方II期2024-03 启动
  11. the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma已完成NCT06549829牵头方不分期2024-05 启动
  12. Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS状态不明NCT06590948牵头方2024-07 启动
  13. Triple Recipient Strategy Using Split, Domino, and Auxiliary Techniques已完成NCT06683820牵头方2023-04 启动
  14. Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study状态不明NCT05598060牵头方不分期2022-11 启动
  15. The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma状态不明NCT05760430牵头方II期2022-12 启动
  16. Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma状态不明NCT05759858牵头方2022-12 启动
  17. Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC状态不明NCT04911959牵头方I/II期2022-07 启动
  18. Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC状态不明NCT04920214牵头方2021-01 启动
  19. Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC状态不明NCT04006275牵头方III期2019-06 启动
  20. Stereotactic Body Radiotherapy and Surgery for Early-stage Hepatocellular Carcinoma状态不明NCT03609151牵头方不分期2018-06 启动
  21. Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma状态不明NCT03732547牵头方II期2018-10 启动
  22. Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma状态不明NCT03609268牵头方不分期2018-06 启动
  23. Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions状态不明NCT04917354牵头方2017-04 启动
  24. The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma状态不明NCT03314532牵头方不分期2017-11 启动
  25. TILA-TACE in Treatment of Hepatocellular Carcinoma状态不明NCT03910140牵头方不分期2017-11 启动
  26. Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis已完成NCT04966195牵头方不分期2015-12 启动
  27. Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma已完成NCT02109146牵头方(推断)III期2014-03 启动
  28. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC即将招募NCT07596134研究中心不分期2026-10 启动
  29. 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness即将招募NCT07100236研究中心2025-08 启动
  30. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  31. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection正在招募NCT06560827研究中心I期2023-10 启动
  32. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  33. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation状态不明NCT03356236研究中心2018-04 启动
  34. Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry已完成NCT03233360研究中心2017-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 59 篇,占 0.6%。

牵头论文
59
2021–2025 年
牵头试验
15
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 151520212022: 9920222023: 111120232024: 131320242025: 11112025

杭州有 9 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 13

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
    分期
    不分期
    开始
    2025-01
    登记号
    NCT06881511

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  2. 正在招募
    Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
    分期
    III期
    开始
    2023-03
    登记号
    NCT05593458

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  3. 正在招募
    Study of Comparing of With and Without Sequential Therapy of S-1
    分期
    III期
    开始
    2023-01
    登记号
    NCT05813015

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  4. 正在招募
    The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
    分期
    不分期
    开始
    2022-01
    登记号
    NCT05323929

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  5. 正在招募
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    分期
    未注明
    开始
    2022-09
    登记号
    NCT06822413

    年龄未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州

  6. 即将招募
    AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07782294

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 2 家列出的医院为研究中心上海、安阳、杭州

  7. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  8. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  9. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  10. 正在招募
    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
    分期
    I/II期
    开始
    2025-08
    登记号
    NCT07070232

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心天津、杭州、武汉、重庆

  11. 正在招募
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    分期
    I期
    开始
    2023-08
    登记号
    NCT06043466

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心杭州

  12. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  13. 即将招募
    Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
    分期
    II期
    开始
    2023-07
    登记号
    NCT05970627

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心宁波、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期早期发现与内镜免疫与靶向药物
论文中的科室消化/肝病科肿瘤内科病理/检验科普外/肝胆胰外科
牵头的论文59
  1. AI-Assisted Detection of Early Gastric Cancer via Visualization of Mucosal Acidity Compromise During Endoscopy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Postoperative survival evaluation of patients with Siewert II adenocarcinoma of esophagogastric junction: a population-based study.2025American journal of surgery
  3. Effects of Neoadjuvant Chemotherapy on Early Postoperative Anxiety and Depression in Patients With Gastric Cancer: An Observational Study.2025Annali italiani di chirurgia
  4. Helicobacter pylori reversing the landscape of neoadjuvant immunotherapy for microsatellite stable gastric cancer: a multicenter cohort study.2025BMC medicine免费全文
  5. Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer.2025Cancer research
  6. A real-world study on the characteristics of autoimmune gastritis: A single-center retrospective cohort in China.2025Clinics and research in hepatology and gastroenterology
  7. Gastric SMARCA4-deficient undifferentiated tumors: clinicopathological analysis of two cases in a single center.2025Diagnostic pathology免费全文
  8. Latent Profile Analysis and Influencing Factors of Fear of Progression in Patients after Endoscopic Submucosal Dissection for Early Gastric Cancer.2025Journal of gastrointestinal cancer
  9. Analysis of the risk of metachronous colorectal cancer and long-term prognosis in patients following gastrectomy for gastric cancer.2025Scientific reports免费全文
  10. CALCR interaction with ANTXR1 drives gastric tumor growth and metastasis via AKT signaling pathway.2025Scientific reports免费全文
  11. Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer.2025The EMBO journal免费全文
  12. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.2024Cancer immunology, immunotherapy : CII免费全文
  13. Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC.2024Cancer science免费全文
  14. Research advances in the molecular classification of gastric cancer.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  15. Causal link between hypothyroidism and gastric cancer risk: insights gained through multivariable Mendelian randomization and mediation analysis.2024Frontiers in endocrinology免费全文
  16. Gastric cancer in pregnancy: a review.2024Future oncology (London, England)免费全文
  17. Refractory Diarrhea and Gastric Adenocarcinoma, Just a Coincidence?2024Gastroenterology
  18. NOX4 regulates gastric cancer cell invasion and proliferation by increasing ferroptosis sensitivity through regulating ROS.2024International immunopharmacology
  19. Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study.2024Journal of gastroenterology and hepatology
  20. Unexpected Multiple Gastrointestinal Cancers in a Patient with Chronic Eosinophilia: A Case Report.2024Journal of gastrointestinal cancer
  21. Identification of oxeiptosis-associated lncRNAs and prognosis-related signature to predict the immune status in gastric cancer.2024Medicine免费全文
  22. Correlation of Neuroendocrine Differentiation with a Distinctively Suppressive Immune Microenvironment in Gastric Cancer.2024Neuroendocrinology免费全文
  23. Two-sample Mendelian randomization analysis of the relationship between periodontitis and risk of upper gastrointestinal cancers.2024Postgraduate medical journal
  24. Predictive modeling of lower extreme deep vein thrombosis following radical gastrectomy for gastric cancer: based on multiple machine learning methods.2024Scientific reports免费全文
  25. Influence of Primary Tumor Resection on Survival of Patients With Metastatic Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Analysis.2023Cancer control : journal of the Moffitt Cancer Center免费全文
  26. Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics.2023Cancer letters
  27. Single-cell characteristics and malignancy regulation of alpha-fetoprotein-producing gastric cancer.2023Cancer medicine免费全文
  28. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.2023Chemotherapy
  29. MAPK4 silencing in gastric cancer drives liver metastasis by positive feedback between cancer cells and macrophages.2023Experimental & molecular medicine免费全文
  30. A 5-Year Follow-Up of a Submucosal Tumor in the Stomach.2023Gastroenterology
  31. Single-Cell Profiling of Tumor Immune Microenvironment Reveals Immune Irresponsiveness in Gastric Signet-Ring Cell Carcinoma.2023Gastroenterology
  32. Gastric microbiota in gastric cancer and precancerous stages: Mechanisms of carcinogenesis and clinical value.2023Helicobacter
  33. Switch/Sucrose Non-Fermentable Complex-Deficient Rhabdoid Carcinoma of Stomach: A Rare Case Report and Literature Review.2023International journal of surgical pathology
  34. Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms.2023Journal of diabetes research免费全文
  35. Iatrogenic metastasis of gastric adenocarcinoma to the abdomen.2023The Pan African medical journal免费全文
  36. Depletion of C12orf48 inhibits gastric cancer growth and metastasis via up-regulating Poly r(C)-Binding Protein (PCBP) 1.2022BMC cancer免费全文
  37. Effects of different pepsinogen cut offs in the screening of apparently healthy people.2022Clinical chemistry and laboratory medicine
  38. Computed tomography in the size measurement of gastric gastrointestinal stromal tumors: Implication to risk stratification and "wait-and-see" tactics.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  39. A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  40. Adverse effects of low serum lipoprotein cholesterol on the immune microenvironment in gastric cancer: a case‒control study.2022Lipids in health and disease免费全文
  41. HER2 protein expression correlates with Lauren classification and P53 in gastric cancer patients.2022Medicine免费全文
  42. HOXC10 indicates poor survival outcome in gastric cancer and promotes G1/S cell cycle transition through transcriptional repression of p21.2022Neoplasma
  43. DeepTI: A deep learning-based framework decoding tumor-immune interactions for precision immunotherapy in oncology.2022SLAS discovery : advancing life sciences R & D
  44. Gastric Metastasis After Tibial Sarcoma Surgery.2022The American journal of gastroenterology
  45. Serum pepsinogen levels in different regions of China and its influencing factors: a multicenter cross-sectional study.2021BMC gastroenterology免费全文
  46. Identification of the angiogenesis related genes for predicting prognosis of patients with gastric cancer.2021BMC gastroenterology免费全文
  47. Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  48. Relationship Between Postoperative Complications and the Prognosis of Gastric Carcinoma Patients Who Underwent Surgical Resection: A Systematic Review and Meta-Analysis.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  49. A clinical model to predict distant metastasis in patients with superficial gastric cancer with negative lymph node metastasis and a survival analysis for patients with metastasis.2021Cancer medicine免费全文
  50. Gastric mucin phenotype indicates aggressive biological behaviour in early differentiated gastric adenocarcinomas following endoscopic treatment.2021Diagnostic pathology免费全文
  51. Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells.2021Drug design, development and therapy免费全文
  52. A scoring model for radiologic diagnosis of gastric leiomyomas (GLMs) with contrast-enhanced computed tomography (CE-CT): Differential diagnosis from gastrointestinal stromal tumors (GISTs).2021European journal of radiology
  53. Current and potential biomarkers in gastric cancer: a critical review of the literature.2021Future oncology (London, England)
  54. A commentary on "Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study" (Int J Surg 2021; 89:105946).2021International journal of surgery (London, England)
  55. "Sweet tooth"-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy.2021Journal of materials chemistry. B
  56. Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival.2021Journal of medical genetics
  57. Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer.2021Journal of nanobiotechnology免费全文
  58. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.2021World journal of gastroenterology免费全文
  59. Decreased exosome-delivered miR-486-5p is responsible for the peritoneal metastasis of gastric cancer cells by promoting EMT progress.2021World journal of surgical oncology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)36
  1. AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis即将招募NCT07782294牵头方2026-09 启动
  2. Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis正在招募NCT06881511牵头方不分期2025-01 启动
  3. The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma正在招募NCT05323929牵头方不分期2022-01 启动
  4. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis正在招募NCT06822413牵头方2022-09 启动
  5. Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer进行中,不再招募NCT06992024牵头方II期2025-04 启动
  6. taVNS Reduces Postoperative Pain and Complications in Patients With Gastric and Intestinal Tumors已完成NCT06763913牵头方不分期2025-01 启动
  7. Metabonomics Study of Chronic Gastritis and Gastric Carcinoma状态不明NCT04624282牵头方2020-11 启动
  8. Nutrition Education Program for Postoperative Patients With Gastric Cancer状态不明NCT03952442牵头方不分期2019-02 启动
  9. Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer状态不明NCT03822130牵头方早期I期2019-02 启动
  10. The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning状态不明NCT04957407牵头方2019-01 启动
  11. Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer状态不明NCT04989153牵头方2016-03 启动
  12. Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1正在招募NCT05593458牵头方(推断)III期2023-03 启动
  13. Study of Comparing of With and Without Sequential Therapy of S-1正在招募NCT05813015牵头方(推断)III期2023-01 启动
  14. Evaluation of Consistency of PDX Model for Predicting Therapeutic Effect of Gastric Cancer状态不明NCT05616533牵头方(推断)2023-09 启动
  15. Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases状态不明NCT05325528牵头方(推断)II/III期2022-04 启动
  16. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  17. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  18. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors正在招募NCT07070232研究中心I/II期2025-08 启动
  19. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  20. Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma即将招募NCT05970627研究中心II期2023-07 启动
  21. A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors正在招募NCT06043466研究中心I期2023-08 启动
  22. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  23. Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration状态不明NCT06396143研究中心2024-07 启动
  24. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia已完成NCT05606094研究中心2023-03 启动
  25. Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma进行中,不再招募NCT05715931研究中心II期2023-05 启动
  26. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  27. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  28. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  29. Study of ESG401 in Adults With Solid Tumors已完成NCT04892342研究中心I/II期2021-09 启动
  30. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  31. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  32. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  33. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer进行中,不再招募NCT04208347研究中心II/III期2019-12 启动
  34. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  35. Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor状态不明NCT03399253研究中心II/III期2017-12 启动
  36. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)已完成NCT02745509研究中心不分期2016-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 1 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Diagnostic Clues and Treatment of Intradural Cranial Chordoma.2016Chinese medical journal

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.7%。

牵头论文
16
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 3320232024: 3320242025: 332025

杭州有 20 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    分期
    II期
    开始
    2023-06
    登记号
    NCT05830123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文16
  1. Soluble immune checkpoint factors reveal high-risk osteosarcoma subtypes and enable early metastasis prediction.2025Frontiers in immunology
  2. Immune-related glycosylation genes based classification predicts prognosis and therapy options of osteosarcoma.2025Gene
  3. HSP47 inhibition-induced CD155 expression through TRAF2 deubiquitination promotes tumor immune evasion.2025Journal for immunotherapy of cancer
  4. PSMD14 is a novel prognostic marker and therapeutic target in osteosarcoma.2024Diagnostic pathology
  5. Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Small Nuclear Ribonucleoprotein Polypeptides B and B1 Promote Osteosarcoma Progression via Activating the Ataxia-Telangiectasia Mutated Signaling Pathway through Ribonucleotide Reductase Subunit M2.2024The American journal of pathology
  7. Human γδ T cells induce CD8+ T cell antitumor responses via antigen-presenting effect through HSP90-MyD88-mediated activation of JNK.2023Cancer immunology, immunotherapy : CII
  8. Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria.2023Cell reports
  9. Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway.2023Medical oncology (Northwood, London, England)
  10. Mitochondria-Targeting Polymer Micelle of Dichloroacetate Induced Pyroptosis to Enhance Osteosarcoma Immunotherapy.2022ACS nano
  11. Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion.2022Nature communications
  12. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.2022Oncoimmunology
  13. Transcription factor ELK1 accelerates aerobic glycolysis to enhance osteosarcoma chemoresistance through miR-134/PTBP1 signaling cascade.2021Aging
  14. Cell Differentiation Trajectory-Associated Molecular Classification of Osteosarcoma.2021Genes
  15. Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes.2021JAMA network open
  16. A panel of eight mRNA signatures improves prognosis prediction of osteosarcoma patients.2021Medicine
早期论文(2016–2020 年)36
  1. 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks.2020Aging
  2. Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  3. TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  5. A Delta-radiomics model for preoperative evaluation of Neoadjuvant chemotherapy response in high-grade osteosarcoma.2020Cancer imaging : the official publication of the International Cancer Imaging Society
  6. Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway.2020International journal of oncology
  7. Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway.2020Journal of orthopaedic surgery and research
  8. Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.2019Biomaterials
  9. Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.2019Frontiers in immunology
  10. Inflammatory responses and biological characteristics of human osteosarcoma cells and umbilical cord blood mononuclear cells in co-cultured microenvironment.2019Journal of biological regulators and homeostatic agents
  11. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.2019Journal of experimental & clinical cancer research : CR
  12. Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations.2019Medical science monitor : international medical journal of experimental and clinical research
  13. Molecular mechanisms of estrogen receptor β-induced apoptosis and autophagy in tumors: implication for treating osteosarcoma.2019The Journal of international medical research
  14. Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma.2018Cancer research
  15. PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway.2018Cell death & disease
  16. MicroRNA-330-3p Expression Indicates Good Prognosis and Suppresses Cell Proliferation by Targeting Bmi-1 in Osteosarcoma.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  17. Survival Prediction in High-grade Osteosarcoma Using Radiomics of Diagnostic Computed Tomography.2018EBioMedicine
  18. Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.2018Frontiers in immunology
  19. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates.2018Frontiers in immunology
  20. Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling.2018Life sciences
  21. Clinical Features and Prognostic Factors in Elderly Ewing Sarcoma Patients.2018Medical science monitor : international medical journal of experimental and clinical research
  22. Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS via Mitochondria-Dependent Pathway.2018Medical science monitor : international medical journal of experimental and clinical research
  23. Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma.2018Medicine
  24. Paeoniflorin induces G2/M cell cycle arrest and caspase-dependent apoptosis through the upregulation of Bcl-2 X-associated protein and downregulation of B-cell lymphoma 2 in human osteosarcoma cells.2018Molecular medicine reports
  25. Zinc phthalocyanine encapsulated in polymer micelles as a potent photosensitizer for the photodynamic therapy of osteosarcoma.2018Nanomedicine : nanotechnology, biology, and medicine
  26. Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice.2017Cancer biology & therapy
  27. Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo.2017Cell death & disease
  28. Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.2017Medicine
  29. Three hematological indexes that may serve as prognostic indicators in patients with primary, high-grade, appendicular osteosarcoma.2017Oncotarget
  30. A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.2017Oncotarget
  31. Overendocytosis of superparamagnetic iron oxide particles increases apoptosis and triggers autophagic cell death in human osteosarcoma cell under a spinning magnetic field.2017Oncotarget
  32. Bio-inspired cisplatin nanocarriers for osteosarcoma treatment.2016Biomaterials science
  33. MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion via Targeting IGF-1R.2016Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  34. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.2016International immunopharmacology
  35. Sinomenine prevents metastasis of human osteosarcoma cells via S phase arrest and suppression of tumor-related neovascularization and osteolysis through the CXCR4-STAT3 pathway.2016International journal of oncology
  36. SIRT1 promotes metastasis of human osteosarcoma cells.2016Oncotarget
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma状态不明NCT05926492牵头方II期2024-01 启动
  2. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma即将招募NCT05590572牵头方I/II期2023-01 启动
  3. Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR状态不明NCT04461223牵头方2019-12 启动
  4. Proteomics Research of Osteosarcoma状态不明NCT03932058牵头方2018-09 启动
  5. Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma状态不明NCT03932071牵头方IV期2017-01 启动
  6. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas正在招募NCT05830123研究中心II期2023-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

杭州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科消化/肝病科
牵头的论文5
  1. A CT-based nomogram established for differentiating gastrointestinal heterotopic pancreas from gastrointestinal stromal tumor: compared with a machine-learning model.2023BMC medical imaging
  2. Duodenal neuroendocrine neoplasms on enhanced CT: establishing a diagnostic model with duodenal gastrointestinal stromal tumors in the non-ampullary area and analyzing the value of predicting prognosis.2023Journal of cancer research and clinical oncology
  3. Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs).2022Abdominal radiology (New York)
  4. Computed tomography in the size measurement of gastric gastrointestinal stromal tumors: Implication to risk stratification and "wait-and-see" tactics.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  5. A scoring model for radiologic diagnosis of gastric leiomyomas (GLMs) with contrast-enhanced computed tomography (CE-CT): Differential diagnosis from gastrointestinal stromal tumors (GISTs).2021European journal of radiology
早期论文(2016–2020 年)7
  1. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.2020Cell death & disease
  2. Endoscopic or laparoscopic resection for small gastrointestinal stromal tumors: a cumulative meta-analysis.2020Chinese medical journal
  3. Diffuse primary extra-gastrointestinal stromal tumor of the peritoneum: A rare case report.2020Medicine
  4. Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors.2020World journal of gastroenterology
  5. Resection of GIST in the duodenum and proximal jejunum: A retrospective analysis of outcomes.2019European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report.2017Medicine
  7. [A case of neurofibromatosis complicated with small bowel obstruction].2016Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

杭州有 8 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 6 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Clinical Features and Prognostic Factors in Elderly Ewing Sarcoma Patients.2018Medical science monitor : international medical journal of experimental and clinical research
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma已完成NCT05046314研究中心II期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。

牵头论文
5
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

杭州有 9 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    不分期
    开始
    2025-11
    登记号
    NCT07359014

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  2. 正在招募
    Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
    分期
    IV期
    开始
    2022-07
    登记号
    NCT05722405

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  3. 正在招募
    To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2026-04
    登记号
    NCT07454187

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心杭州、苏州、西安、郑州

  4. 正在招募
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    分期
    III期
    开始
    2024-06
    登记号
    NCT06508983

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州

  5. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药CAR-T 与细胞治疗复发与耐药
论文中的科室肿瘤内科影像/核医学科
牵头的论文5
  1. CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial.2025Cancer immunology research
  2. Using protein turnover assay to explore the drug mechanism of Carfilzomib.2024Acta biochimica et biophysica Sinica免费全文
  3. Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019.2024Journal of global health免费全文
  4. New diagnostic strategy for multiple myeloma: A review.2023Medicine免费全文
  5. (-)-Epigallocatechin-3-gallate plays an antagonistic role in the antitumor effect of bortezomib in myeloma cells via activating Wnt/β-catenin signaling pathway.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma正在招募NCT07359014牵头方不分期2025-11 启动
  2. Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma正在招募NCT05722405牵头方IV期2022-07 启动
  3. Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma状态不明NCT04706936牵头方I期2021-04 启动
  4. To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma正在招募NCT07454187研究中心I/II期2026-04 启动
  5. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients正在招募NCT06508983研究中心III期2024-06 启动
  6. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  7. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  8. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  9. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies进行中,不再招募NCT04684108研究中心I期2021-11 启动
  10. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma状态不明NCT04674514研究中心I/II期2021-04 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

杭州有 4 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题治疗方案遗传与家族性
论文中的科室风湿免疫科神经外科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

杭州有 5 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 7 篇,占 1.4%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 1120232024: 0020242025: 002025

杭州有 3 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断孕期、儿童与老人视神经与视力
论文中的科室神经内科
牵头的论文7
  1. Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder with cholangiocarcinoma: Casual or causal association?2023CNS neuroscience & therapeutics免费全文
  2. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.2022Epilepsia
  3. Case Report: Neuromyelitis Optica Spectrum Disorder With Progressive Elevation of Cerebrospinal Fluid Cell Count and Protein Level Mimicking Infectious Meningomyelitis: A Diagnostic Challenge.2022Frontiers in immunology免费全文
  4. Late-onset neuromyelitis optica spectrum disorder mimicking stroke in an elderly Chinese man: Case report.2022The journal of spinal cord medicine免费全文
  5. Neuromyelitis optica spectrum disorder complicated with Sjögren's syndrome: first pediatric case responsive to mycophenolate mofetil treatment.2021Acta neurologica Belgica
  6. Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population.2021Journal of neurology
  7. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.2021Multiple sclerosis (Houndmills, Basingstoke, England)
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动
  2. A Study of LP-168 in Healthy Volunteers已完成NCT05432713研究中心I期2022-05 启动
PubMed 以外找到的论文(未计入)2
  1. Choroid Plexus Cysts on 7T MRI Differentiate NMOSD from MS2025medRxiv预印本
  2. Criteria for myelin oligodendrocyte glycoprotein antibody‐associated disease: Balancing underdiagnosis with overdiagnosis2023Clinical and Translational Discovery论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

杭州有 6 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题胸腺与胸腺切除抗体与诊断
论文中的科室神经内科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 12 篇,占 3.4%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 6620242025: 112025

杭州有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07894107

    年龄 12 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与脑血流血管重建手术儿童
论文中的科室影像/核医学科神经外科神经内科
牵头的论文12
  1. Unraveling the links between intracranial artery stenosis, cerebral perfusion, and white matter hyperintensity in moyamoya disease.2026European radiology
  2. Glymphatic dysfunction in moyamoya disease: The influence of arterial stenosis and ventricular enlargement.2025NeuroImage
  3. White matter hyperintensities in cholinergic pathways correlates of cognitive impairment in moyamoya disease.2024European radiology
  4. Glymphatic System Impairment in the Advanced Stage of Moyamoya Disease.2024Journal of neuroscience research
  5. Exploring the Impact of Hemoglobin on Cerebral Blood Flow in Arterial Territories and Surgical Outcomes: Potential Implications for Moyamoya Disease Treatment.2024Journal of the American Heart Association免费全文
  6. The effects of anastomoses between anterior and posterior circulation on postoperative prognosis of patients with moyamoya disease.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology免费全文
  7. Altered neurovascular coupling and structure-function coupling in Moyamoya disease affect postoperative collateral formation.2024Scientific reports免费全文
  8. Hemodynamic Effects of Tortuosity and Stenosis in Superficial Temporal Artery-Middle Cerebral Artery Bypass for Moyamoya Disease.2024World neurosurgery
  9. Efficacy assessment of superficial temporal artery-middle cerebral artery bypass surgery in treating moyamoya disease from a hemodynamic perspective: a pilot study using computational modeling and perfusion imaging.2023Acta neurochirurgica
  10. Preoperative Brain Functional Connectivity Improve Predictive Accuracy of Outcomes After Revascularization in Moyamoya Disease.2023Neurosurgery免费全文
  11. Abnormal brain functional and structural connectivity between the left supplementary motor area and inferior frontal gyrus in moyamoya disease.2022BMC neurology免费全文
  12. Comparison of Operative and Conservative Treatment for Asymptomatic Moyamoya Disease: Preliminary Experience in Small Retrospective Series.2021World neurosurgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome正在招募NCT07894107研究中心2026-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 8 篇,占 4.0%。

牵头论文
8
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 2220232024: 0020242025: 112025

杭州有 3 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease
    分期
    未注明
    开始
    2004-01
    登记号
    NCT04965545

    年龄 6 岁 至 65 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  2. 正在招募
    Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
    分期
    未注明
    开始
    2004-01
    登记号
    NCT04965558

    年龄 6 岁 至 65 岁(登记的条件)

    牵头:浙江大学医学院附属第二医院杭州

  3. 正在招募
    Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
    分期
    III期
    开始
    2026-09
    登记号
    NCT07465718

    年龄 8 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传学(ATP7B)诊断与铜代谢检测治疗(螯合剂、锌剂)
论文中的科室神经内科
牵头的论文8
  1. Neuroimaging correlates of genetics in patients with Wilson's disease.2025Cerebral cortex (New York, N.Y. : 1991)
  2. Structures of the human Wilson disease copper transporter ATP7B.2023Cell reports
  3. Pathogenicity of Intronic and Synonymous Variants of ATP7B in Wilson Disease.2023The Journal of molecular diagnostics : JMD
  4. Emerging neurological symptoms after liver transplantation: A 6-year follow-up of an adolescent patient with Wilson's disease.2022CNS neuroscience & therapeutics免费全文
  5. Serum Neurofilament Light Chain in Wilson's Disease: A Promising Indicator but Unparallel to Real-Time Treatment Response.2022Movement disorders : official journal of the Movement Disorder Society
  6. Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson's Disease.2021Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  7. Prevalent Pathogenic Variants of ATP7B in Chinese Patients with Wilson's Disease: Geographical Distribution and Founder Effect.2021Genes免费全文
  8. Challenges and suggestions for precise diagnosis and treatment of Wilson's disease.2021World journal of pediatrics : WJP
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease正在招募NCT04965558牵头方2004-01 启动
  2. Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease正在招募NCT04965545牵头方2004-01 启动
  3. The Individual Therapy for Patients With Wilson's Disease状态不明NCT03957720牵头方早期I期2019-03 启动
  4. Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients已完成NCT04965571牵头方2010-09 启动
  5. Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.正在招募NCT07465718研究中心III期2026-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025

杭州有 6 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 3 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.即将招募NCT06766552牵头方2025-01 启动
  2. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis即将招募NCT07451665研究中心IV期2026-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

杭州有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。

牵头论文
6
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 2220232024: 2220242025: 002025

杭州有 10 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
    分期
    I期
    开始
    2024-12
    登记号
    NCT06556394

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、成都、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Clinical characterization and founder effect analysis in Chinese amyotrophic lateral sclerosis patients with SOD1 common variants.2024Annals of medicine
  2. FUS reads histone H3K36me3 to regulate alternative polyadenylation.2024Nucleic acids research
  3. Clinical feature difference between juvenile amyotrophic lateral sclerosis with SPTLC1 and FUS mutations.2023Chinese medical journal
  4. Pathogenicity classification of SOD1 variants of uncertain significance by in vitro aggregation propensity.2023Neurobiology of aging
  5. Taste loss as the sole presenting symptom in Chinese patient with facial onset sensory and motor neuronopathy.2021CNS neuroscience & therapeutics
  6. Aberrant Stress Granule Dynamics and Aggrephagy in ALS Pathogenesis.2021Cells
早期论文(2016–2020 年)2
  1. Sensory nerve disturbance in amyotrophic lateral sclerosis.2018Life sciences
  2. Amyotrophic Lateral Sclerosis: Precise Diagnosis and Individualized Treatment.2017Chinese medical journal
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis状态不明NCT04518540牵头方不分期2020-09 启动
  2. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation正在招募NCT06556394研究中心I期2024-12 启动
  3. A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS即将招募NCT07169175研究中心I/II期2025-12 启动
  4. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis即将招募NCT06645197研究中心早期I期2024-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

杭州有 7 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease正在招募NCT07187440研究中心2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年没有牵头庞贝病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 2 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
论文中的科室神经内科
中文论文(未计入)1
  1. [Multiple disciplinary team for Pompe disease].2023Zhonghua nei ke za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 7 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.即将招募NCT06766552牵头方2025-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 4 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

杭州有 10 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 2 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

杭州有 3 家医院列在先天性膈疝下全国有 44 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 3 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文1
  1. Mesenteric Neural Crest Cells Are the Embryological Basis of Skip Segment Hirschsprung's Disease.2021Cellular and molecular gastroenterology and hepatology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 1 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
论文中的科室风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 4 篇,占 6.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 2220232024: 0020242025: 002025

杭州有 4 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年没有牵头Leber 遗传性视神经病变的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 5 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Mitochondrial tRNAThr 15891C>G mutation was not associated with Leber's hereditary optic neuropathy in Han Chinese patients.2016Mitochondrial DNA. Part A, DNA mapping, sequencing, and analysis

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

浙江大学医学院附属第二医院

Second Affiliated Hospital, Zhejiang University

杭州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Second Affiliated Hospital of Zhejiang University; Second Affiliated Hospital of Zhejiang University of Medicine; Second Affiliated Hospital Zhejiang University; Second Affiliated Hospital Zhejiang University College of Medicine; Second Affiliated Hospital of Zhejiang University Medical College; SAHZU

提出更正下载数据